Search

Author/Creator Strik, Ankie

1. ATIM-42. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: OS CORRELATIONS WITH INITIAL AND MAXIMUM CD4+T LYMPHOCYTE COUNT IN THE PERIPHERAL BLOOD. (11th November 2019)

Authors:
Bota, Daniela; Taylor, Thomas; Xiao-Tang, Kong; Fu, Beverly; Alsharif, Mohamad; Pretto, Chrystel; Strik, Ankie; Schijns, Virgil; Stathopoulos, Apostolos
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 6
Page Start:
vi10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS. (9th November 2020)

Authors:
Bota, Daniela; Taylor, Thomas; Kong, Xiao-Tang; Fu, Beverly; Hsu, Frank; Strik, Ankie; Schijns, Virgil; Stathopoulos, Apostolos
Journal:
Neuro-oncology
Issue:
Volume 22(2020)Supplement 2
Page Start:
ii34
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. (29th August 2018)

Authors:
Bota, Daniela A; Chung, Jinah; Dandekar, Manisha; Carrillo, Jose A; Kong, Xiao-Tang; Fu, Beverly D; Hsu, Frank PK; Schönthal, Axel H; Hofman, Florence M; Chen, Thomas C; Zidovetzki, Raphael; Pretto, Chrystel; Strik, Ankie; Schijns, Virgil EJC; Stathopoulos, Apostolos
Journal:
CNS oncology
Issue:
Volume 7:Number 3(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search